{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:09:05Z","timestamp":1760044145506,"version":"3.44.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.amjcard.2012.06.005","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T23:04:02Z","timestamp":1343257442000},"page":"1200-1206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic Strategies to Reduce Adverse Clinical Outcomes in Patients With Acute Coronary Syndrome"],"prefix":"10.1016","volume":"110","author":[{"given":"David","family":"Brieger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1016\/j.amjcard.2012.06.005_bib1","first-page":"e18","article-title":"Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/j.amjcard.2012.06.005_bib2","first-page":"S430","article-title":"Burden of disease: medical and economic impact of acute coronary syndromes","volume":"12","author":"Turpie","year":"2006","journal-title":"Am J Manag Care"},{"issue":"suppl","key":"10.1016\/j.amjcard.2012.06.005_bib3","first-page":"e25","article-title":"Heart disease and stroke statistics\u20142008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"117","author":"Rosamond","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.005_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.107.188209","volume":"117","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.005_bib5","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.005_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib7","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","article-title":"Pathophysiology of coronary artery disease","volume":"111","author":"Libby","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.005_bib8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2012.06.005_bib9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2012.06.005_bib10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2012.06.005_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heart.83.3.361","article-title":"The pathophysiology of acute coronary syndromes","volume":"83","author":"Davies","year":"2000","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2012.06.005_bib12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events During Observation","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2012.06.005_bib13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib14","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199207163270301","article-title":"Reactivation of unstable angina after the discontinuation of heparin","volume":"327","author":"Th\u00e9roux","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jacc.2003.05.014","volume":"42","author":"Bijsterveld","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.005_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction","volume":"90","author":"Merlini","year":"1994","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/j.amjcard.2012.06.005_bib19","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/S0735-1097(02)02776-6","article-title":"Oral anticoagulants in patients with coronary artery disease","volume":"41","author":"Anand","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.005_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2012.06.005_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0735-1097(00)01118-9","article-title":"Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina","volume":"37","year":"2001","journal-title":"J Am Coll Cardiol"},{"year":"2011","series-title":"Xarelto [package insert]","key":"10.1016\/j.amjcard.2012.06.005_bib23"},{"year":"2011","series-title":"Pradaxa [package insert]","key":"10.1016\/j.amjcard.2012.06.005_bib24"},{"year":"2011","series-title":"Eliquis [summary of product characteristics]","key":"10.1016\/j.amjcard.2012.06.005_bib25"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2012.06.005_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1538-7836.2007.02552.x","article-title":"Factor Xa or thrombin: is thrombin a better target?","volume":"5","author":"Weitz","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2012.06.005_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2012.06.005_bib29","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2012.06.005_bib30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2012.06.005_bib31","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1111\/j.1538-7836.2005.01557.x","article-title":"Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction","volume":"3","author":"Christersson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2012.06.005_bib32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib33","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/157016110790226688","article-title":"Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism","volume":"8","author":"Yong","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.amjcard.2012.06.005_bib36","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2012.06.005_bib37","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.005_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib39","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","article-title":"Predictors of hospital mortality in the Global Registry of Acute Coronary Events","volume":"163","author":"Granger","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib40","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non\u2013ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC\/AHA guidelines) bleeding score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.005_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2012.06.005_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.005_bib43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2005.09.060","article-title":"A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes","volume":"47","author":"Rao","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.005_bib44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.005_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction","volume":"350","year":"1997","journal-title":"Lancet"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914912015366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914912015366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:25:08Z","timestamp":1757571908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914912015366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0002914912015366"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2012.06.005","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Strategies to Reduce Adverse Clinical Outcomes in Patients With Acute Coronary Syndrome","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2012.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}